Schizophrenia News

Sleep problems during early childhood may be associated with the onset of psychosis and borderline personality disorder, or BPD, in adolescence, according to results of a cohort study published in JAMA Psychiatry.

Researchers have uncovered important factors associated with the switch from mania to depression among individuals with bipolar 1 disorder, according to results of a prospective observational study published in Journal of Clinical Psychiatry.

Cognitive behavioral therapy may reduce the risk for first psychosis episode among individuals at clinical high risk for psychosis, according to results of a systematic review and meta-analyses published in Journal of Clinical Psychiatry.

Several pharmacologic treatments, including vitamin E, may reduce symptoms of tardive dyskinesia, or TD, according to results of a meta-analysis and systematic review published in Journal of Clinical Psychiatry.

Clinicians should use caution when prescribing antipsychotics and benzodiazepines to treat patients with dementia because of an apparent increased risk for death, according to a study published in Journal of Clinical Psychiatry.

An intervention that integrated behavioral counseling, care management and care coordination for patients with serious mental illness significantly reduced overall CV risk, researchers reported.

An academic detailing intervention was not associated with a significant reduction of antipsychotic prescribing in nursing homes, according to results of a cluster randomized clinical trial published in JAMA Network Open.

Adjunctive pimavanserin significantly improved outcomes among patients with predominant negative symptoms of schizophrenia, according to data presented at the American Society of Clinical Psychopharmacology Annual Meeting.

Most ENLIGHTEN-2 extension study participants who completed exit interviews reported satisfaction with ALKS 3831 treatment, according to data presented at the American Society of Clinical Psychopharmacology Annual Meeting.

An antipsychotic with a novel mechanism of action appeared effective and safe among hospitalized patients with schizophrenia, according to data presented at the American Society of Clinical Psychopharmacology Annual Meeting.